Item 5. Market for Registrant’s Common Equity
Item
5. Market for Company’s Common Equity, Related Stockholder Matters and Small Business Issuer Purchases of Equity Securities
Market
Information
Since
February 1, 2022, the principal market on which our unit is traded is the Nasdaq Capital Market. Our common share, warrant and right
have traded on the Nasdaq since March 24, 2022. The Company’s unit is trading under the symbol “ACAXU,” common
stock is trading under symbol “ACAX,” our warrant is trading under the symbol “ACAXW,” and the right is
trading under the symbol “ACAXR.”
Prior
to our listing on the Nasdaq Capital Market there was no public trading market for our securities.
Holders
As
of February 24, 2023, the Company had two stockholders of record.
Dividends
Since
inception we have not paid any dividends on our common stock. We currently do not anticipate paying any cash dividends in the foreseeable
future on our common stock. Although we intend to retain our earnings, if any, to finance the exploration and growth of our business,
our board of directors will have the discretion to declare and pay dividends in the future. Payment of dividends in the future will depend
upon our earnings, capital requirements, and other factors, which our board of directors may deem relevant.
Securities
authorized for issuance under equity compensation plans.
The
Company does not have securities authorized for issuance under any equity compensation plans
Performance
graph
Not
applicable to smaller reporting companies.
Recent
sales of unregistered securities; use of proceeds from registered securities
On
November 8, 2021, our Sponsor purchased 2,156,250 founder shares for an aggregate purchase price of $25,000, or approximately $0.012
per share. Such securities were issued pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities
Act. Prior to the initial investment in the company of $25,000 by our Sponsor, the Company had no assets, tangible or intangible.
The per share purchase price of the founder shares was determined by dividing the amount of cash contributed to the Company by the
aggregate number of founder shares issued. The number of founder shares issued was determined based on the expectation that the
founder shares would represent 20% of the outstanding shares after the Initial Public Offering (excluding the placement units and
underlying securities). As such, our initial stockholders collectively own approximately 23.6% of our issued and outstanding
shares.
On
February 3, 2022, we consummated our Initial Public Offering (the “Offering”) of an aggregate of 8,625,000 units (“Units”)
including the issuance of 1,125,000 Units as a result of the underwriter’s full exercise of its over-allotment option. The Units
were sold at an offering price of $10.00 per Unit, generating gross proceeds of $86,250,000.
Simultaneously
with the consummation of the Offering, the Company consummated the private placement of 473,750 units (the “Private Placement Units”)
to the Sponsor, including the issuance of 33,750 Private Placement Units in connection with the underwriter’s full exercise of
its over-allotment option, at a price of $10.00 per Private Placement Unit, generating total gross proceeds of $4,735,500 (the “Private
Placement”). The Private Placement was conducted as a non-public transaction and, as a transaction by an issuer not involving a public offering, is
exempt from registration under the Securities Act in reliance upon Section 4(a)(2) of the Securities Act.
24
Of
the gross proceeds received from the Offering, including the full exercise of the over-allotment option, and the Private Placement Units,
$86.25 million and $4.7 million was placed in the Trust Account, respectively.
On
February 3, 2022, the Company paid a cash underwriting discount of $0.20 per Unit, or $1,725,000. In addition, the underwriters are entitled
to a deferred fee of $0.35 per Unit, or $3,018,750 in the aggregate. The deferred fee will become payable to the underwriters from the
amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the
underwriting agreement.
Purchases
of Equity Securities by the issuer and affiliated purchasers
The
Company did not repurchase any shares of the Company’s common stock during 2022.
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.